LIFECORE BIOMEDICAL, INC. Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax
LIFECORE BIOMEDICAL, INC. (LFCR) reported Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax of $265.00 thousand for the 3-month period ending 2019-08-25, per its 10-Q filed 2019-10-03.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax · last filed 2019-10-03
- LIFECORE BIOMEDICAL, INC. other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, tax for the quarter ending 2019-08-25 was $265.00K.
| Period end | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax 3 month |
|---|---|
| 2019-08-25 | $265.00K 10-Q · filed 2019-10-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |